Investigating Natalizumab Through Further Observational Research and Monitoring

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Incidence of serious and/or clinically significant infections, malignancies, and other SAEs in patients with CD treated with TYSABRI®

Authority:

United States: Food and Drug Administration

Study ID:

ELN100226-CD451

NCT ID:

NCT00707512

Start Date:

June 2008

Completion Date:

Related Keywords:

• Crohn's Disease
• Crohn Disease